  0 Table of Contents |
  1 Home |
| 2 Background |
 3 Artifacts Summary |
 3.1 ICR Administrative Coverage Measure |
| 3.2 ICR Campaign Readiness Measure |
| 3.3 ICR Geographic Coverage Measure |
| 3.4 ICR MDA Treatment Coverage Measure |
| 3.5 ICR Survey Coverage Measure |
| 3.6 ICR Zero-dose Coverage Measure |
| 3.7 ICR Campaign Readiness Checklist |
| 3.8 ICR MDA Supervision Checklist |
| 3.9 ICR Administrative Coverage |
| 3.10 ICR Adverse Event |
| 3.11 ICR Campaign |
| 3.12 ICR Campaign Activity |
| 3.13 ICR Campaign Protocol |
| 3.14 ICR Campaign Task |
| 3.15 ICR Care Team |
| 3.16 ICR Consent (Person-Data Governance) |
| 3.17 ICR Delivery Unit (Household / Community) |
| 3.18 ICR Immunization Event |
| 3.19 ICR Location |
| 3.20 ICR Medication Administration |
| 3.21 ICR Patient (Registered Individual) |
| 3.22 ICR Supervision Report |
| 3.23 ICR Supply Delivery |
| 3.24 ICR Survey Coverage |
| 3.25 ICR Target Population |
| 3.26 Campaign Round |
| 3.27 Coverage Source |
| 3.28 Coverage Unit |
| 3.29 Delivery Strategy |
| 3.30 Denominator Source |
| 3.31 Denominator Type |
| 3.32 Directly Observed Consumption |
| 3.33 Dose-pole Band |
| 3.34 Eligible Persons Absent |
| 3.35 Eligible Persons Present |
| 3.36 Estimate Confidence |
| 3.37 Estimate Date |
| 3.38 Exclusion Reason |
| 3.39 Finger Marked |
| 3.40 Group Location |
| 3.41 Houses Visited |
| 3.42 Is Planning Denominator |
| 3.43 Location Boundary (GeoJSON) |
| 3.44 Missed Reason |
| 3.45 Noncompliance Reason |
| 3.46 Overlays Admin Unit |
| 3.47 Oversees Area |
| 3.48 Planning Denominator |
| 3.49 Prior-dose Status (Zero-dose) |
| 3.50 Real-time vs Reconciled |
| 3.51 Record Origin |
| 3.52 Revisit Outcome |
| 3.53 Sample Design |
| 3.54 Serious-Event Criteria |
| 3.55 Settlement / Special-population Type |
| 3.56 Social Mobilization |
| 3.57 Stock Accountability |
| 3.58 Target Geography |
| 3.59 Task Origin |
| 3.60 Workload Target |
| 3.61 ICR Adverse Event Causality |
| 3.62 ICR Adverse Event Seriousness |
| 3.63 ICR Campaign Type |
| 3.64 ICR Communication Channel |
| 3.65 ICR Coverage Source |
| 3.66 ICR Coverage Stratifier |
| 3.67 ICR Coverage Unit |
| 3.68 ICR Data Lineage |
| 3.69 ICR Delivery Strategy |
| 3.70 ICR Denominator Source |
| 3.71 ICR Denominator Type |
| 3.72 ICR Dose History / Zero-dose Status |
| 3.73 ICR Exclusion Reason |
| 3.74 ICR Group Kind |
| 3.75 ICR Independent Coverage Source |
| 3.76 ICR Location Type |
| 3.77 ICR MDA Medication |
| 3.78 ICR MDA Medicine Package |
| 3.79 ICR Missed Reason |
| 3.80 ICR Noncompliance Reason |
| 3.81 ICR NTD Disease |
| 3.82 ICR Record Origin |
| 3.83 ICR Revisit Outcome |
| 3.84 ICR Serious-Event Criteria |
| 3.85 ICR Settlement / Special-population Type |
| 3.86 ICR Supplied Item |
| 3.87 ICR Task Origin |
| 3.88 ICR Team Role |
| 3.89 ICR Adverse Event Causality |
| 3.90 ICR Campaign Type |
| 3.91 ICR Communication Channel |
| 3.92 ICR Coverage Source |
| 3.93 ICR Coverage Stratifier |
| 3.94 ICR Coverage Unit |
| 3.95 ICR Data Lineage |
| 3.96 ICR Delivery Strategy |
| 3.97 ICR Denominator Source |
| 3.98 ICR Denominator Type |
| 3.99 ICR Dose History / Zero-dose Status |
| 3.100 ICR Exclusion Reason |
| 3.101 ICR Group Characteristic |
| 3.102 ICR Group Kind |
| 3.103 ICR Location Type |
| 3.104 ICR MDA Medicine Package |
| 3.105 ICR Missed Reason |
| 3.106 ICR Noncompliance Reason |
| 3.107 ICR NTD Disease |
| 3.108 ICR Project Tag |
| 3.109 ICR Record Origin |
| 3.110 ICR Revisit Outcome |
| 3.111 ICR Serious-Event Criteria |
| 3.112 ICR Settlement / Special-population Type |
| 3.113 ICR Task Origin |
| 3.114 ICR Team Role |
| 3.115 ICR ↔ WHO IMMZ AEFI Causality |
| 3.116 Administer albendazole — MDA activity definition |
| 3.117 Administer MCV — campaign activity definition |
| 3.118 Administrative coverage — Kambia MR SIA, June 2026 round |
| 3.119 Adverse event — abdominal pain following albendazole |
| 3.120 AEFI — anaphylaxis following MCV dose (serious) |
| 3.121 AEFI — fever following MCV dose |
| 3.122 Albendazole administration — MDA register entry |
| 3.123 Albendazole receipt — Rokupr community (ATC-coded drug supply) |
| 3.124 Care team — CDD team 7, Rokupr |
| 3.125 Community-directed MDA — Rokupr, albendazole round |
| 3.126 Distribute ITNs — activity definition |
| 3.127 ESPEN MDA — 1. Location Registration Form |
| 3.128 ESPEN MDA — 2. Medicine Receipt Form |
| 3.129 ESPEN MDA — 3. Medicine Treatment Form (tally) |
| 3.130 ESPEN MDA — 4. Medicine Use & Case Management Form |
| 3.131 ESPEN MDA — 5. Supervision: Health Facility |
| 3.132 ESPEN MDA — 6. Supervision: CDD Observation |
| 3.133 Example Child |
| 3.134 Example Community — Rokupr |
| 3.135 Example Consent — registry data sharing |
| 3.136 Example Country |
| 3.137 Example District |
| 3.138 Example Dwelling |
| 3.139 Example Fixed Post — Rokupr CHC |
| 3.140 Example Head of Household |
| 3.141 Example Household |
| 3.142 Example Household — fully enumerated |
| 3.143 Example Settlement |
| 3.144 Example Sibling |
| 3.145 Example Supervisory Area |
| 3.146 Example Target Population — children 9m–14y, Kambia District |
| 3.147 Example Target Population — children 9m–14y, Kambia District (enumeration estimate) |
| 3.148 Example Target Population — children 9m–14y, Sierra Leone (national) |
| 3.149 Follow-up revisit — missed child, Rokupr block 4 |
| 3.150 Geographic coverage — Kambia MDA (villages treated / total) |
| 3.151 ITN delivery to household |
| 3.152 Kambia MR SIA — June 2026 round |
| 3.153 MCV dose — campaign record |
| 3.154 MDA treatment coverage — Rokupr albendazole round (sex × age stratified) |
| 3.155 Measles–Rubella SIA Protocol |
| 3.156 Mop-up household visit — Rokupr block 4, house 12 |
| 3.157 Post-campaign survey coverage — Kambia MR SIA, June 2026 round |
| 3.158 Readiness validation — Kambia supervision zone 2 |
| 3.159 Sierra Leone MR SIA 2026 — national umbrella campaign |
| 3.160 Site session — Rokupr CHC fixed post, campaign day 3 |
| 3.161 Spray structure — IRS activity definition |
 3.162 Supervision report — CDD observation, Rokupr |
